Supernus Pharmaceuticals, Inc. (SUPN) vs Xeris Biopharma Holdings, Inc. (XERS)
- Supernus Pharmaceuticals, Inc. SUPN 37.88 −4.27%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
Supernus Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Supernus Pharmaceuticals, Inc. is the larger, with a market value of $2.3B against $1.8B — 1.2× the size. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 36.3% against 24.9%. Xeris Biopharma Holdings, Inc. has the higher net margin (−5.12% vs −13.2%) and the higher return on invested capital (18.9% vs −12.4%). Across the 18 metrics below, Xeris Biopharma Holdings, Inc. leads on 13 and Supernus Pharmaceuticals, Inc. on 5.
Valuation
Profitability
| Metric | SUPN | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 88.07% | 86.58% | 53.94% |
| Operating margin | (15.71%) | 10.91% | 0.00% |
| Net margin | (13.23%) | (5.12%) | 0.00% |
| Free cash flow margin | 2.21% | 16.60% | 0.00% |
| Return on equity | (10.49%) | 118.22% | (0.40%) |
| Return on assets | (7.82%) | (4.60%) | (3.32%) |
| Return on invested capital | (12.37%) | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack